Last updated on April 16, 2014 at 7:44 EDT

Latest David T. Curiel Stories

2013-12-24 13:28:00

Working in mice, researchers at Washington University School of Medicine in St. Louis report developing a gene delivery method long sought in the field of gene therapy: a deactivated virus carrying a gene of interest that can be injected into the bloodstream and make its way to the right cells. In this early proof-of-concept study, the scientists have shown that they can target tumor blood vessels in mice without affecting healthy tissues. "Most current gene therapies in humans involve...

2012-10-23 07:28:41

HOUSTON, Oct. 23, 2012 /PRNewswire/ -- DNAtrix, Inc., the Houston-based biotechnology company developing targeted adenovirus-based oncolytic virus products for brain cancer, announced today a merger with VectorLogics, Inc. (VLI), a company with a complementary intellectual property portfolio developing products for ovarian cancer. The merged company will retain the name DNAtrix and continue to develop its lead cancer product, DNX-2401, which is in clinical testing at the University of Texas...